Kyntra Bio, Inc. (KYNB)vsEli Lilly and Company (LLY)
KYNB
Kyntra Bio, Inc.
$7.27
+3.12%
HEALTHCARE · Cap: $28.37M
LLY
Eli Lilly and Company
$934.60
+9.80%
HEALTHCARE · Cap: $760.43B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 1011996% more annual revenue ($65.18B vs $6.44M). KYNB leads profitability with a 2849.0% profit margin vs 31.7%. LLY earns a higher WallStSmart Score of 78/100 (B+).
KYNB
Avoid26
out of 100
Grade: F
LLY
Strong Buy78
out of 100
Grade: B+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 2849 of every $100 in revenue as profit
Mega-cap, among the largest globally
Every $100 of equity generates 101 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 44.9%
Revenue surging 42.6% year-over-year
Earnings expanding 51.4% YoY
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
Revenue declined 59.3%
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 31.5x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : KYNB
The strongest argument for KYNB centers on Profit Margin. Profitability is solid with margins at 2849.0% and operating margin at -1059.0%.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.7% and operating margin at 44.9%. Revenue growth of 42.6% demonstrates continued momentum.
Bear Case : KYNB
The primary concerns for KYNB are EPS Growth, Market Cap, Return on Equity.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Key Dynamics to Monitor
KYNB profiles as a declining stock while LLY is a growth play — different risk/reward profiles.
KYNB carries more volatility with a beta of 0.90 — expect wider price swings.
LLY is growing revenue faster at 42.6% — sustainability is the question.
LLY generates stronger free cash flow (678M), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 26/100), backed by strong 31.7% margins and 42.6% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Kyntra Bio, Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is headquartered in San Francisco, California.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?